Immatics N.V. - Ordinary Shares (NQ:IMTX)

9.090 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 16, 2026 Add to My Watchlist

Price and Volume

Volume	605
Open	9.090
Bid (Size)	3.640 (200)
Ask (Size)	10.96 (100)
Prev. Close	9.090
Today's Range	9.090 - 9.090
52wk Range	5.050 - 12.41
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

June 01, 2026

From https://immatics.com/

Via GlobeNewswire

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

May 31, 2026

From https://immatics.com/

Via GlobeNewswire

Performance

YTD	-13.0%	-13.0%
1 Month	-14.4%	-14.4%
3 Month	-7.5%	-7.5%
6 Month	-9.9%	-9.9%
1 Year	+49.0%	+49.0%

More News

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

May 30, 2026

From https://immatics.com/

Via GlobeNewswire

Immatics Appoints Amie Krause as Chief People Officer

October 27, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Appoints Venkat Ramanan as Chief Financial Officer

October 01, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Announces First Quarter 2026 Financial Results and Business Update

May 12, 2026

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

April 21, 2026

From https://immatics.com/

Via GlobeNewswire

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

April 17, 2026

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Full Year 2025 Financial Results and Business Update

March 05, 2026

From https://immatics.com/

Via GlobeNewswire

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

December 11, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Announces $125 Million Underwritten Offering

December 05, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Third Quarter 2025 Financial Results and Business Update

November 17, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

November 12, 2025

From https://immatics.com/

Via GlobeNewswire

Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures

October 20, 2025

Via MarketMinute

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

October 20, 2025

From https://immatics.com/

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 02, 2025

Via Benzinga

Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

August 19, 2025

Via Benzinga

Immatics Announces Second Quarter 2025 Financial Results and Business Update

August 13, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

May 31, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Announces First Quarter 2025 Financial Results and Business Update

May 13, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

April 23, 2025

From https://immatics.com/

Via GlobeNewswire

Immatics Announces Full Year 2024 Financial Results and Business Update

March 27, 2025

From https://immatics.com/

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 03, 2025

Via Benzinga

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

November 18, 2024

From https://immatics.com/

Via GlobeNewswire

Frequently Asked Questions

Is Immatics N.V. - Ordinary Shares publicly traded?

Yes, Immatics N.V. - Ordinary Shares is publicly traded.

What exchange does Immatics N.V. - Ordinary Shares trade on?

Immatics N.V. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Immatics N.V. - Ordinary Shares?

The ticker symbol for Immatics N.V. - Ordinary Shares is IMTX on the Nasdaq Stock Market

What is the current price of Immatics N.V. - Ordinary Shares?

The current price of Immatics N.V. - Ordinary Shares is 9.090

When was Immatics N.V. - Ordinary Shares last traded?

The last trade of Immatics N.V. - Ordinary Shares was at 06/16/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.